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Introduction
Acute Renal Failure (ARF) remains a common and signiﬁ  cant problem in modern medicine. The 
epidemiology and causes of ARF vary according to the clinical setting; in intensive care units it is 
estimated that the incidence of ARF ranges from 10%–25%,
1,2 with acute tubular necrosis (ATN) 
accounting for about 75% of cases.
3
Recent data from the BEST kidney investigators has estimated the worldwide prevalence of ARF 
that is likely to require renal replacement therapy (RRT) amongst ICU patients to be as high as 5.7%, 
and is associated with a high hospital mortality rate.
4 Despite recent major advances in the knowledge 
of the underlying mechanisms leading to kidney dysfunction, only small improvements have been made 
with respect to its prevention and treatment, and ARF continues to be a major contributor to in-hospital 
mortality.
5,6
While past clinical trials in patients with ARF have been hampered by the lack of a standardized 
deﬁ  nition of ARF, recent meetings have resulted in validated stages of ARF as deﬁ  ned by the RIFLE 
criteria.
7,8 These well-deﬁ  ned stages of ARF allow current trials to be standardized with respect to 
measures of kidney dysfunction, which is essential when evaluating patients for ARF. However, there 
still remains much improvements to be made in increasing the sensitivity of current markers of acute 
kidney injury (AKI). Creatinine is currently the most widely-used marker of renal function. Its use in 
the diagnosis of ARF remains a problem, however, as it often requires as much as a 50% loss in renal 
function before creatinine levels rise.
7 The fact that the many different therapeutic agents that have been 
tried in ARF have shown very little success is perhaps explained by this delay in diagnosing ARF, which 
has been compared to beginning the treatment of acute myocardial infarction 48–72 hours after the 
coronary occlusion.
9
For these reasons, there has been a search for better markers of early AKI in recent years, which 
have seen the advent of several promising new biomarkers of renal function in this setting. This review 
will discuss some of these promising biomarkers and their potential as useful markers of AKI. A lit-
erature search performed on MEDLINE/PubMed using the search terms ‘renal insufﬁ  ciency, acute’ and 
‘biological markers’ yielded 414 results, of which relevant articles were selected from all publication 
types in the English language, from either human or animal models.
10
Diagnosis of ARF
Current diagnosis of ARF relies on standard markers of renal function, and is usually accomplished 
through elevations in the levels of serum creatinine, urea, and urinalysis changes. Recently, RIFLE 
criteria have been described with regards to the use of these indices in the diagnosis of ARF.
7 Brieﬂ  y, 
ARF was deﬁ  ned as a spectrum initially starting with a risk of kidney injury (R criterion) with an 
increase in baseline creatinine  50% or urine output  0.5 mL/kg/h for 6 hours, to end-stage renal 
disease (E criterion) with anuria  3 months. Acute tubular necrosis (ATN), being the most common 
cause of ARF in hospitalized patients, is sometimes mistakenly used interchangeably with ARF. ATN, 
however, is a subset of ARF which results from ischemic or toxic injury to the renal tubular cells as 
opposed to other causes of ARF which include prerenal azotemia, urinary tract obstruction, vasculitis, 
glomerulonephritis, or interstitial nephritis. The distinction of ATN from these other causes of ARF has 
been reviewed in recent years and remains largely based on a combination of clinical history, physical 
examination and the standard laboratory studies mentioned above.
7,11,12,13116
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Plasma creatinine, while being the most 
commonly used marker of renal function, is a 
suboptimal marker of ARF for several reasons. It 
is well known that factors such as liver dysfunction 
(leading to decreased creatinine production from 
creatine), low muscle mass, increased tubular 
secretion of creatinine in low-ﬂ  ow states, drug 
interference with tubular handling, and increased 
volume of distribution in critically ill patients 
frequently lead to an overestimation of renal func-
tion from serum creatinine measurements.
7,11,12,13 
Moran and Myers observed various opposed pat-
terns of plasma creatinine change with regards to 
the measured glomerular ﬁ  ltration rate (GFR) in 
the non-steady state that represents ARF, demon-
strating the inaccuracy of simple creatinine mea-
surements in this setting.
14
Blood urea nitrogen (BUN) determination has 
also been used extensively in the evaluation of 
kidney function. Levels of BUN also present sev-
eral confounding factors as they depend on exog-
enous urea load, endogenous production, and 
tubular reabsorption, which is increased in states 
of reduced effective renal perfusion.
15 Like cre-
atinine, its use in the diagnosis of ARF has there-
fore not been without limitations.
Renal Tubular Cell Proteins 
and Enzymes
N-acetyl-β-D-Glucosaminidase
and tubular brush-border enzymes
Several enzymes originating from proximal tubular 
cells have been investigated as markers of necrotic 
damage whose urinary levels are increased following 
proximal tubule injury or dysfunction. Their use as 
markers of proximal tubular injury has been reviewed 
recently.
16 The acute or chronic damage of the renal 
tubular cells is believed to cause the release of 
these enzymes from the renal tubules into the urine 
where they can be measured. Many urinary enzymes 
were studied in the last 25 years, originating broadly 
from the lysosomes, the brush-border membrane and 
the cytoplasm of the renal tubular cells. N-acetyl-
β-D-Glucosaminidase (NAG), found predominantly 
in proximal tubule lysosomes, has been the most 
extensively studied of these enzymes in ARF in 
various contexts including nephrotoxic agents, ATN, 
after cardiac surgery or renal transplantation.
17–23 
Other enzymes that have been investigated include 
alkaline phosphatase (AP), alanine amino-peptidase 
and γ-glutamyl transpeptidase (GGT), which are 
enzymes found in the brush-border membrane, 
while the different isoforms of glutathione-S-
tranferase (α and γ GST) are cytosolic enzymes.
24 
The measurement of such enzymes is currently done 
by automated assays usually via immunonephelo-
metric methods or ELISA.
However, despite the fact that enzymuria clearly 
reﬂ  ects tubular injury, the clinical signiﬁ  cance of 
enzymuria regarding early diagnosis of ARF has 
been questionned as it may not always imply pro-
gression towards clinical renal failure.
23,25 Like-
wise, it has been shown on several occasions that 
contrast administration during coronary angiogra-
phy or arteriography provoked an elevation in 
urinary NAG, however again without necessarily 
progressing towards clinically apparent renal fail-
ure.
26–28 Similarly, NAG has been known to be 
elevated in other types of kidney diseases, such as 
diabetic nephropathy, perhaps limiting its useful-
ness in this setting.
29
In a small study involving 26 ICU patients of 
whom 4 developed ARF (deﬁ  ned as a creatinine 
increase  50% or  0.15 mmol/L) Westhuyzen 
et al. evaluated urinary NAG, GGT, AP, α/γ GST, 
and lactate dehydrogenase (LDH) values at ICU 
admission in the early detection of ARF.
30 Receiver-
operating curve (ROC) analysis for GGT, α and 
γ-GST, AP and NAG was performed despite the low 
number of events (area under curve of 0.95, 0.92, 
0.89, 0.86 and 0.84 respectively), while the ROC 
analysis for LDH and creatinine clearance was lower 
albeit still signiﬁ  cant. Plasma creatinine detected 
the onset of ARF between 12–96 hours after admis-
sion, and BUN determination was unhelpful in 
diagnosing ARF. Tubular enzymuria at admission 
in the ICU was thus useful in their small ICU 
sample in predicting the development of ARF, and 
more so in ruling out the development of ARF.
A known limitation of enzymuria, however, 
concerns the inability of these enzymes to help 
differentiate between the different clinical causes 
of ARF. Chew et al. were unable to differentiate 
between the various etiologies of ARF using NAG, 
intestinal-type AP and tissue non-speciﬁ  c alkaline 
phosphatase, in 50 patients with ARF (n = 16 for 
prerenal ARF, n = 28 for renal ARF, and n = 6 for 
post-renal ARF).
18 Similarly (see KIM-1 study 
below), Han et al. could not differentiate between 
the causes of ARF in their cohort of 32 patients 
with ARF using GGT and AP.
31117
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In an interesting study, Herget-Rosenthal 
evaluated the usefulness of tubular proteinuria and 
enzymuria for predicting the need for renal 
replacement therapy (RRT) in 73 patients who 
developed non-oliguric ARF due to ATN, of whom 
26 required RRT.
32 All patients with established 
non-oliguric ARF fulﬁ  lling ATN criteria were 
included in the study and had their urine collected 
on the day of inclusion for levels of α-1 and β-2 
microglobulins, cystatin C, retinol-binding pro-
tein, α-GST, GGT, LDH, and NAG. Patients 
requiring RRT had signiﬁ  cantly increased NAG 
values as opposed to patients who did not, and the 
area under the ROC curve was 0.81 for urinary 
NAG values above 4.5 U/mmol of urinary creati-
nine. However the sensitivity/speciﬁ  city of urinary 
NAG for RRT was lower than that of cystatin C 
and α-1-microglobulin, being 85%/62%. Patients 
who required RRT also had signiﬁ  cantly higher 
urinary values of cystatin C and α-1-microglobulin 
than patients who did not require RRT. The other 
markers evaluated (retinol-binding protein, 
β-2-microglobulin, GST, GGT, LDH) showed less 
ability to predict the need for RRT.
Liangos et al. obtained concordant results lately 
in a study that evaluated both NAG and KIM-1 
(see below for KIM-1). Higher levels of both NAG 
and KIM-1 were associated with higher odds ratio 
for dialysis requirement or hospital death in a larger 
cohort of 201 patients separated in four different 
quartiles according to NAG values.
33 Of note, there 
were no statistical differences in creatinine values 
between the 4 different quartiles, despite differ-
ences in the proportion of patients requiring RRT. 
Unfortunately, the NAG values for the four differ-
ent quartiles were not reported.
Overall, these studies indicate that quantifying 
enzymuria remains a sensitive, albeit not very spe-
ciﬁ  c, tool for establishing the presence of a renal 
tubular injury. Recent studies have suggested a 
promising role for NAG in helping to predict 
adverse outcomes in ARF, and future studies should 
try to validate these results in larger cohorts.
Kidney injury molecule-1 (KIM-1)
KIM-1 was originally described as a putative epi-
thelial cell adhesion molecule upregulated in rat 
renal proximal tubules after renal ischemic injury 
by Ichimura et al. in 1998.
34 While its role remains 
unclear, it consists in a transmembrane protein 
whose ectodomain is shed into the urine where it 
can be measured. In a subsequent study involving 
32 patients with various forms of acute and chronic 
renal disease published in 2002, urinary KIM-1 
levels were shown to be signiﬁ  cantly more elevated 
in patients with ATN as opposed to patients with 
other causes of ARF or chronic renal disease.
31 The 
7 patients with ischemic ATN had mean normalized 
urinary KIM-1 values of 2.92 +/− 0.61, while the 
remaining patients with ARF had mean values of 
0.63 +/− 0.17, p   0.01 (16 total patients, 7 with 
contrast nephropathy, 5 with prerenal azotemia, 2 
with cyclosporine toxicity, 1 with post-obstructive 
nephropathy and 1 with interstitial nephritis). 
Patients with chronic renal diseases had mean 
normalized values of 0.72 +/− 0.37, p   0.01 (n = 9, 
diseases included Wegener’s granulomatosis, sys-
temic lupus erythematosus nephropathy, diabetic 
nephropathy, focal segmental glomerulosclerosis, 
and chronic allograft dysfunction). Of note, the 
definition of ARF used in the study was 1) 
increase in serum creatinine  0.5 mg/dL if baseline 
 2.0 mg/dL, or 2) increase in serum creatinine 
 1.5 mg/dL if baseline  2.0 mg/dL, or 3) increase 
in serum creatinine  0.5 mg/dL regardless of 
baseline if as a consequence of exposure to contrast 
agents. Urinary AP and GGT were also measured 
but were not helpful in differentiating ATN from 
other causes of renal injury.
Since then, urinary KIM-1 levels have been 
shown to be increased in rodents receiving neph-
rotoxic doses of cisplatin, folic acid, cadmium, 
gentamycin, mercury and chromium,
35–39 suggest-
ing a role of KIM-1 for detecting nephrotoxic 
insults. Also, Liangos et al. demonstrated very 
recently in a cohort of 201 patients with ARF 
separated in quartiles according to their urinary 
levels of KIM-1, that higher levels correlated with 
a higher odds ratio for dialysis requirement or 
hospital death, adding some prognostic value to 
the measured levels of urinary KIM-1.
33 As with 
NAG values however, the actual values of the dif-
ferent KIM-1 by quartiles were not reported. These 
results all suggest a useful role of KIM-1 in detect-
ing renal ischemic injuries, but further studies from 
larger cohorts will be required to validate this 
biomarker in current practice.
Na
+/H
+ exchanger isoform 3 (NHE3)
The NHE3 is the most abundant of all recently 
detected sodium transporters expressed in the neph-
ron and can be detected in urine.
40 It is localized in 118
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the apical membrane and subapical endosomes of 
renal proximal tubular cells and in the apical mem-
brane of thick ascending limb cells,
41–43 and is 
responsible for 60%–70% of the reabsorption of 
the ﬁ  ltered sodium.
44 Du Cheyron et al. measured 
the urinary levels of NHE3 in 68 patients admit-
ted to the ICU, 54 of whom either had or developed 
ARF during their ICU stay (deﬁ  ned as an increase 
in serum creatinine to  177 μmol/L or to a value 
 50% of basal creatinine when chronic renal insuf-
ﬁ  ciency existed).
45 Patients with ARF were divided 
into 3 subgroups according to clinical criteria: 
prerenal azotemia (which improved rapidly after 
volume replacement), ATN (deﬁ  ned as renal dys-
function that did not improve after correction of 
possible prerenal causes and could not be attributed 
to other causes), and intrinsic ARF other than ATN. 
In this population, levels of urinary NHE3 normal-
ized for urine creatinine were increased six times 
as much in patients with ATN than in those with 
prerenal azotemia (0.78 +/− 0.36 vs. 0.12 +/− 0.08, 
p   0.001), while urinary NHE3 could not be 
detected in the 14 control ICU patients without 
ARF. Urinary RBP was also measured but could 
not discriminate between prerenal ARF and ATN.
Urinary actin
Kwon et al. evaluated urinary actin in a study that 
also looked at interleukin-6 (IL-6), interleukin-8 
(IL-8), GGT, LDH, and tumor necrosis factor-alpha 
(TNFα) in 40 kidney transplant recipients during 
the ﬁ  rst post-transplant week.
46 Actin is the main 
cytoskeletal protein in cells, and damage to the 
cellular cytoskeleton has been described as one of 
the key events following renal ischemia-reperfusion 
injury.
47,48 Of these 40 patients, 9 out of the 30 patients 
receiving cadaveric allografts progressed to 
sustained ARF (deﬁ  ned as a creatinine clearance 
 25 mL/min by 24 hour urine collection at day 7 
post-operatively), while the remaining 21 went on 
to a recovery phase (deﬁ  ned as a creatinine clear-
ance above 25 mL/min). All 10 patients receiving 
living donor allografts progressed to a recovery 
phase. In their study urinary actin at day 0 was 
elevated in recipients destined to have sustained 
ARF, with ROC analyses for urinary actin at day 
0 yielded values of 0.75. This suggests that urinary 
actin might serve as a predictor of sustained ARF 
after kidney transplantation from cadaveric 
allografts, but larger studies will be required to 
further explore the role of urinary actin in AKI.
Exosomal fetuin A
All nephron segments secrete exosomes containing 
apical membrane and intracellular ﬂ  uid into the 
urine under normal conditions and thus may poten-
tially carry protein markers of structural damage 
to the nephrons. Exosomal fetuin A, an acute phase 
protein involved in various inﬂ  ammatory states, 
was very recently identiﬁ  ed using urinary pro-
teomics techniques from a rat models of cisplatin-
induced nephrotoxicity and ischemic-reperfusion 
injury as a potential marker of AKI in these set-
tings.
49 Urinary exosomal fetuin A was then also 
shown in the same study to be elevated in 3 ICU 
patients with AKI compared to the patients without 
AKI. Fetuin A might thus be a potential urinary 
biomarker of AKI, and will need to be investigated 
in larger studies.
Cysteine-rich protein 61 (Cyr61)
Cyr61 is a secreted heparin-binding protein that 
may possibly be involved in tissue growth and 
repair,
50,51 which was originally described as a 
growth factor-inducible immediate early gene in 
ﬁ  broblasts.
52 It was identiﬁ  ed by Muramatsu et al. 
in 2002 by representational difference analysis as 
one of the genes that was rapidly induced follow-
ing ischemia in rodent models of ischemic/reper-
fusion injury.
53 The urinary levels of Cyr61 in 
rodents could be detected as early as three to six 
hours following renal injury, where it might even-
tually serve as an early biomarker of ARF. More 
studies will be required to validate its use in 
humans.
Sulfated HNK-1 epitope
The HNK-1 carbohydrate epitope is attached to 
lactosamine structures on glycoproteins, proteogly-
cans, or glycolipids and has been known to be an 
important actor in neurogenesis and immune sys-
tems
54,55 through proposed involvement in cell-cell 
interactions and cell migration.
56 Such interactions 
are likely to be involved in renal morphogenesis, 
as Allory et al. demonstrated in 2006 the expression 
of the HNK-1 epitope mainly to the thin ascending 
loop of Henle in adult kidneys.
57 Furthermore, in 
10 kidney biopsies from patients with ATN after 
renal transplantation, the HNK-1 epitope was found 
to be expressed at various levels in 8 of these cases, 
thus raising the possibility of its use as a potential 
marker for ATN.119
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Urinary Low-Molecular
Weight Proteins
Urinary excretion of low-molecular weight (LMW) 
proteins, like that of renal proximal tubular 
enzymes, has also been extensively described in 
the biomarker literature over the last 25 years. 
These LMW proteins are usually freely ﬁ  ltered and 
then reabsorbed by the proximal tubule under 
normal conditions.
58 In settings of tubular damage 
where such reabsorption is impaired, or in contexts 
of increased reabsorptive load with increased 
transglomerular passage of proteins, these proteins 
cannot be entirely reabsorbed and are therefore 
secreted in urine.
59 These proteins that have been 
used as biomarkers of tubular dysfunction include 
β-2-microglobulin, α-1-microglobulin, retinol-
binding protein (RBP), and cystatin C.
In a study from 2004 described previously, 
Herget-Rosenthal evaluated the usefulness of tubu-
lar proteinuria and enzymuria for predicting the 
need for RRT in 73 patients who developed non-
oliguric ARF due to ATN, of whom 26 required 
RRT.
32 Patients who required RRT had signiﬁ  -
cantly higher urinary values of cystatin C and 
α-1-microglobulin than patients who did not require 
RRT. The area under the ROC curves for these two 
proteins was 0.92 and 0.86 respectively, and with 
a sensitivity/speciﬁ  city of 92%/83% and 88%/81% 
respectively, at values of urinary cystatin C  1g/mol 
of creatinine and α-1-microglobulin  20g/mol of 
creatinine. As said previously, patients requiring 
RRT also had signiﬁ  cantly increased NAG values 
as opposed to patients who did not, however the 
sensitivity/speciﬁ  city of urinary NAG for RRT was 
lower than that of cystatin C and α-1-microglobulin. 
The other markers evaluated (RBP, β-2-
microglobulin, GST, GGT, LDH) showed less 
ability to predict the need for RRT.
While these results appear promising for 
cystatin C and α-1-microglobulin, previous studies 
involving the latter had shown that while being a 
sensitive marker of tubular injury, elevations in 
α-1-microglobulin were not always associated with 
clinically relevant renal injury,
60–62 which is simi-
lar to the use of several renal biomarkers described 
previously in this review.
Cystatin C
Cystatin C is a low molecular weight protein func-
tioning as a lysosomal cysteine protease inhibitor, 
and is therefore strongly implicated in the 
regulation of proteolytic damage of these 
enzymes.
63 Cystatin C is considered one of the 
housekeeping genes and is produced at a constant 
rate by all nucleated cells, without changes with 
aging, gender, or muscular mass. By virtue of its 
low molecular weight, it is freely ﬁ  ltered at the 
glomerulus and is completely catabolized by 
proximal tubules.
64–66 These characteristics thus 
make cystatin C a good marker of glomerular ﬁ  ltra-
tion rate whose reliability is comparable or superior 
to plasma creatinine, and has been demonstrated 
in several clinical settings.
65,67–72 In ARF, however, 
there exist only a few clinical studies which 
evaluated cystatin C. Hergert-Rosenthal demon-
strated the clinical signiﬁ  cance of cystatin C in 
ARF.
73 In this study, serum cystatin C and serum 
creatinine were measured daily in 85 critically ill 
patients at high risk of developing ARF. In the 
44 patients with ARF (classiﬁ  ed according to the 
recent RIFLE criteria
7), a signiﬁ  cant early rise in 
cystatin C detected a risk of renal injury (R criteria, 
elevation of  50% from baseline creatinine) 
1.5 +/− 0.6 days before a rise in serum creatinine. 
Applying the same analysis to renal injury and 
renal insufﬁ  ciency (I and F criteria) also detected 
these conditions earlier in a similar fashion. 
Regarding the need for RRT, an elevation of 
cystatin C  50% predicted RRT requirements 
moderately well, with a sensitivity of 53% and 
speciﬁ  city of 82%. Herget-Rosenthal also demon-
strated the use of urinary cystatin C in 2004 in 
predicting the need for RRT in patients with non-
oliguric ARF due to ATN, as just described.
32
Also, Ahlström et al. measured serum cystatin C 
daily starting from admission to the ICU in 202 
patients.
74 ARF (deﬁ  ned here as a threefold increase 
in baseline creatinine, or in case of chronic renal 
failure as an increase  0.5 to 4.0 mg/dL of cre-
atinine, or diuresis  0.3 mL/kg/h for 24 h, or the 
need for RRT) occurred in 54 patients, and cystatin 
C was as useful as creatinine in detecting ARF. 
Plasma creatinine, however, was already at a mean 
of 255 μmol/L at ICU admission in the group of 
patients that developed ARF (with mean peak 
values of plasma creatinine of 294 μmol/L), and 
RRT was started on day 2 on average, suggesting 
pre-existing advanced renal dysfunction at the time 
of study inclusion. When only considering abnor-
mal values of creatinine that developed after ICU 
admission (defined in the protocol as  90 or 
95 μmol/L for females and males, respectively), 
both serum cystatin C and plasma creatinine 120
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appeared equally quickly (median 3 days). It is 
unspeciﬁ  ed if any of those 29 patients went on to 
develop ARF, however.
Of note, one small study has produced conﬂ  ict-
ing results regarding the use of cystatin C in ARF. 
It involved 29 critically ill septic patients of which 
10 developed ARF (deﬁ  ned here as creatinine 
 267 μmol/L or diuresis  30 mL/h, duration not 
speciﬁ  ed), cystatin C was not found to be correlated 
with the occurrence of ARF, as opposed to mea-
surements of the N-terminal prohormone of atrial 
natriuretic peptide (proANP).
75 It is unclear from 
this study how many patients required RRT.
Still, another small study from Delanaye et al. 
showed that the ability of cystatin C to detect a 
GFR   80 cc/min/1.73m
2 (GFR calculated by 
Cockroft-Gault estimation or by 24h creatinine 
clearance) was superior than plasma creatinine in 
14 ICU patients.
76 Similarly, a report from ten 
patients undergoing unilateral nephrectomy for 
transplantation purposes also demonstrated that 
serum cystatin C increased by 50 to 100% postop-
eratively 1.4 +/− 0.9 days earlier than creatinine 
(p = 0.009).
77
Finally, in 2006, a study by Zhu et al. demon-
strated the ability of serum cystatin C in detecting 
acute renal dysfunction (deﬁ  ned as a creatinine 
clearance below 80 mL/min/1.73m
2 measured by 
24 h urine collection) in 60 patients undergoing 
heart valve replacement.
78 Cystatin C levels peaked 
at post-operative day 2 on average as opposed to 
day 3 for creatinine, and cystatin C levels signiﬁ  -
cantly rose in 19 of the 26 patients developing acute 
renal dysfunction while only 7 of these patients 
demonstrated an elevated serum creatinine. Inter-
estingly, ‘low-dose’ corticosteroid therapy (dexa-
methasone 10 mg daily for 3 days after surgery, 
n = 26) did not result in any changes in measured 
serum cystatin C when compared to patients not 
receiving any corticosteroids. Increased serum 
cystatin C levels have been reported in patients 
receiving corticosteroids,
79–82 but other investiga-
tors have reported so only after large, prolonged 
doses.
80
It should also be noted that in settings of radio-
contrast nephropathies, an evaluation of the neph-
rotoxic effect of contrast administered during 
coronary angiography demonstrated a signiﬁ  cant 
elevation of cystatin C (+7.2%) 24 hours after 
angiography, while the serum creatinine rise could 
only be seen 48 hours after, also suggesting a role 
of cystatin C in the diagnosis of AKI.
83 Likewise, 
in a study by Bachorzewska-Gajewska evaluating 
NGAL in coronary angiographies, the levels of 
serum cystatin C were also signiﬁ  cantly elevated 
24 hours after coronary angiography (from 1.69 
+/−1.03 to 2.85 +/−2.05 mg/L, p   0.01), while 
serum creatinine remained unaffected.
84
Cystatin C is a well-established marker of GFR 
in settings of stable renal function and chronic renal 
insufﬁ  ciency.
65–72 Taken together, the results of the 
studies just described also seem to suggest a pos-
sible role for serum cystatin C in detecting AKI, 
and perhaps especially for urinary cystatin C, also 
in predicting adverse outcomes in ARF such as 
RRT. In view of the several conﬂ  icting studies, it 
seems likely however that larger studies will be 
required to clarify the role of cystatin C in ARF.
Neutrophil gelatinase-associated 
lipocalin (NGAL)
NGAL is a part of the lipocalin protein family 
and is a 23 kDa low molecular weight protein 
secreted by various types of human cells, which 
include not only activated neutrophils
85 but also 
other tissues such as the kidneys, and cells of the 
gastro-intestinal and respiratory tracts.
86–91 NGAL 
is also strongly expressed by various types of 
carcinomas and adenomas. Its physiologic role 
seems complex, implying cell growth and dif-
ferentiation, a bacteriostatic immune effect and a 
role in cellular iron-transport pathways.
92 By 
virtue of its small size NGAL is freely ﬁ  ltered by 
the renal glomeruli without being reabsorbed, and 
can therefore be measured in the urine. Early 
studies by Mishra et al. in 2003 using cDNA 
microarray assay methods allowed its identiﬁ  ca-
tion as a protein strongly expressed in renal 
tubules in animal models of renal ischemic 
injury.
93 Interestingly, NGAL might act in a pro-
tective fashion for the renal tubules in this context, 
as seem to indicate some animal studies.
94
In humans, the role of this new biomarker in 
settings of AKI has now been demonstrated. In a 
recent study by Mishra et al. urinary and plasma 
NGAL levels were measured in 71 children under-
going cardiac surgery necessitating extra-corporeal 
cardio-pulmonary bypass.
95 Amongst the 20 chil-
dren developing AKI (deﬁ  ned as an elevation of 
serum creatinine  50% from baseline), a signiﬁ  -
cant rise in the average urinary NGAL levels was 
seen as early as 2 hours post-operatively (from 
1.6 μg/L SE 0.3, to 147 μg/L SE not available), 121
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while a signiﬁ  cant change in serum creatinine 
could only be noted from 24 to 72 hours post-
operatively. Using a urinary NGAL cutoff value 
of 50 μg/L and looking at the 51 children not 
developing AKI as case-controls, the urinary 
NGAL level 2 hours after CPB showed an impres-
sive 100% sensitivity and 98% speciﬁ  city in the 
early diagnosis of AKI. Plasma NGAL levels 
showed similar results although sensitivity and 
speciﬁ  city of the test were somewhat lower than 
for urinary NGAL in the study. A similar study in 
adults after cardiac surgery also demonstrated a 
signiﬁ  cant increase in urinary NGAL 1 hour after 
surgery, however without being adequately pow-
ered to obtain sensitivity and speciﬁ  city values.
96
Interestingly, Bachorzewska-Gajewska recently 
demonstrated a rise in urinary NGAL 4 hours fol-
lowing the administration of contrast during per-
cutaneous coronary angioplasties in 25 adult 
patients (from 11.1 μg/L +/−15.8 to 17.8 +/− 34.48, 
p   0.05) despite however any signiﬁ  cant change 
in average serum creatinine values.
84 These studies 
thus suggest a very promising role for NGAL in 
the early evaluation of ARF which will require 
further investigations.
Urinary interleukin-18 (IL-18)
and other cytokines
IL-18 is a cytokine with several important roles in 
human immune defense mechanisms, principally 
acting as a co-stimulator in the production of 
gamma-interferon, a crucial element in the human 
defenses against infections. At the renal level, 
recent animal studies in mice by Melnikov dem-
onstrated the possible role played by IL-18 in the 
renal tubules in settings of acute ischemic tubular 
necrosis.
97,98
It was then demonstrated in humans that the 
urinary concentration of IL-18 was higher in ATN 
when compared with other causes of renal insuf-
ﬁ  ciency such as hypovolemia, heart failure, urinary 
tract infections and chronic renal failure (n = 72).
99 
In the same study, the urinary IL-18 level at 24 
hours after kidney graft was also much higher in 
patients who later developed delayed graft dys-
function. The same investigators also looked at a 
cohort of 72 children undergoing cardiac surgery 
requiring cardio-pulmonary bypass.
100 They dem-
onstrated a signiﬁ  cant increase in the urinary IL-18 
level starting only 4 hours after surgery in the 20 
children who developed an acute renal injury 
(as defined by an increase  50% of baseline 
creatinine in the 3 days after surgery) when com-
pared to 35 case-controls chosen amongst the 
50 children without renal insufﬁ  ciency. The sen-
sitivity and speciﬁ  city of IL-18 in this context 
seemed best between 12 and 24 hours with values 
of 40%–50% and 94% respectively, for urinary 
IL-18 levels higher than 50 pg/mL. The area under 
the ROC was 0.73 and 0.75 for these levels of IL-
18 at 12 and 24 hours. One other case-control study 
with urinary samples from 52 cases and 86 control-
cases (controlled for demographic factors, sepsis, 
baseline creatinine, APACHE III score, and diure-
sis) involved in the ARDS Network Study demon-
strated a relationship between a rise  100 ng/mL 
of IL-18 at 24 and 48 hours and the development 
of ARF.
101 This rise in urinary IL-18 was also 
associated with higher mortality amongst these 
patients.
These studies thus indicate a possible role for 
urinary IL-18 in the early evaluation of ARF, and 
also an ability to differentiate between some of the 
causes of ARF. Once again, more studies will be 
needed to validate these early results.
Interleukin-6, interleukin-8, and tumor necrosis 
factor-alpha are other inﬂ  ammatory cytokines that 
have been implicated in the cascade of cellular 
events that follows renal ischemic injury.
102–104 
Their role in the detection of AKI was investigated 
in a study by Kwon et al. (mentioned previously) 
in the context of early kidney transplant graft 
rejection.
46 In their study, IL-6 and IL-8 (but not 
TNFα) at day 0 were elevated in recipients destined 
to have sustained ARF. ROC analyses for urinary 
IL-6, and IL-8 at day 0 yielded values of 0.91, and 
0.82 respectively. Such results thus suggest that 
these markers might serve as strong predictors of 
sustained ARF after kidney transplantation, but 
larger studies should obviously be done to ascertain 
these early results.
The Future Search for Biomarkers
As several recent reviews have mentioned, the 
recent advent of several new biomarkers, each 
representing a different aspect of the various causes 
of ARF (see Table 1), is likely to continue as our 
understanding of the different molecular mecha-
nisms involved in ARF evolves.
105,106 Through 
genomics and proteomics, recent studies have 
looked at the different genes and proteins expressed 
during different models of ARF and identiﬁ  ed 122
Naud and Leblanc
Biomarker Insights 2008:3
several other candidate biomarkers.
107 Several 
studies using cDNA microarray methods have 
already identified many genes that are either 
upregulated or downregulated in animal models of 
ARF.
108,113–115 A recent study also demonstrated the 
differential gene expression between different 
models of ARF that included nephrotoxic injury, 
ischemic injury and hypovolemia.
108 As seen in 
this study however, a frequent problem with 
genomic approaches is that modiﬁ  cations in gene 
transcription do not always result in altered protein 
expression because of various post-transcriptional 
events. Changes at the genomic level therefore also 
need to be evaluated in terms of changes in func-
tional protein levels. Another exciting approach 
has been through the recent development of the 
ﬁ  eld of proteomics, and particularly of the urinary 
proteome.
109 This approach focuses on the pattern 
of urinary protein expression using mass spectrom-
etry to identify the proteins implicated with the 
cause of renal disease. In recent years, proteomics 
has proven to be a powerful tool in investigation 
and clinical medicine, and will likely eventually 
provide us with a comprehensive knowledge of the 
various proteins that can be found in the urine 
under many conditions.
109–112 An important prob-
lem with proteomics is however to ensure the 
stability of the proteome from the collection to 
analysis for there are several factors that might 
alter samples.
112 Also the functional role of the 
various proteins identiﬁ  ed might not necessarily 
be directly proportional to their amount, and the 
identiﬁ  cation of scarce compounds requires meth-
ods with high sensitivity which can prove to be 
difﬁ  cult. Finally, standards will have to be estab-
lished for means of comparison. Still, the research 
potential of these methods is obviously enormous, 
and one should expect large amounts of data to 
come forward from these in the next years as our 
knowledge and techniques evolve.
There are therefore many different biomarkers 
of kidney function that each reflect different 
aspects of renal physiology, and which are all 
affected differently in the various conditions that 
result in ARF. Genomics and proteomics have 
already yielded extremely interesting insights in 
our understanding of the pathophysiology of the 
various forms of ARF and their associated potential 
biomarkers, and will undoubtebly continue to do 
so in the next few years. It is likely that no single 
marker will prove to have the required sensitivity 
and specificity required for all these different 
diagnoses, and we will most likely depend on a 
panel of some of the markers implicated in the 
various forms of ARF in its different phases to 
properly diagnose ARF in the future.
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